131 related articles for article (PubMed ID: 11449376)
1. Down-regulation of human alloimmune responses by genetically engineered expression of CD95 ligand on stimulatory and target cells.
Dulat HJ; von Grumbkow C; Baars W; Schröder N; Wonigeit K; Schwinzer R
Eur J Immunol; 2001 Jul; 31(7):2217-26. PubMed ID: 11449376
[TBL] [Abstract][Full Text] [Related]
2. Mature but not immature Fas ligand (CD95L)-transduced human monocyte-derived dendritic cells are protected from Fas-mediated apoptosis and can be used as killer APC.
Hoves S; Krause SW; Halbritter D; Zhang HG; Mountz JD; Schölmerich J; Fleck M
J Immunol; 2003 Jun; 170(11):5406-13. PubMed ID: 12759415
[TBL] [Abstract][Full Text] [Related]
3. CD95 ligand-expressing tumors are rejected in anti-tumor TCR transgenic perforin knockout mice.
Behrens CK; Igney FH; Arnold B; Möller P; Krammer PH
J Immunol; 2001 Mar; 166(5):3240-7. PubMed ID: 11207278
[TBL] [Abstract][Full Text] [Related]
4. Different susceptibility of cytotoxic T cells to CD95 (Fas/Apo-1) ligand-mediated cell death after activation in vitro versus in vivo.
Ehl S; Hoffmann-Rohrer U; Nagata S; Hengartner H; Zinkernagel R
J Immunol; 1996 Apr; 156(7):2357-60. PubMed ID: 8786290
[TBL] [Abstract][Full Text] [Related]
5. [The CD95/CD95L system as target for modulation of allogeneic immune responses].
Schwinzer R; Dulat H; Kyas U; Wonigeit K
Langenbecks Arch Chir Suppl Kongressbd; 1998; 115(Suppl I):655-8. PubMed ID: 14518336
[TBL] [Abstract][Full Text] [Related]
6. Limitations of CD95 ligand-transduced killer dendritic cells to prevent graft rejections.
Kusuhara M; Matsue H
Exp Dermatol; 2005 Apr; 14(4):273-80. PubMed ID: 15810885
[TBL] [Abstract][Full Text] [Related]
7. Membrane-bound CD95 ligand expressed on human antigen-presenting cells prevents alloantigen-specific T cell response without impairment of viral and third-party T cell immunity.
Strauss G; Osen W; Knape I; Jacobsen EM; Müller SM; Debatin KM
Cell Death Differ; 2007 Mar; 14(3):480-8. PubMed ID: 16902496
[TBL] [Abstract][Full Text] [Related]
8. Functional role of CD95 ligand in concanavalin A-induced intestinal intraepithelial lymphocyte cytotoxicity.
Ghoreschi K; Muders M; Enders GA
Immunology; 1998 Dec; 95(4):566-71. PubMed ID: 9893046
[TBL] [Abstract][Full Text] [Related]
9. CD95/Fas signaling in human melanoma cells: conditional expression of CD95L/FasL overcomes the intrinsic apoptosis resistance of malignant melanoma and inhibits growth and progression of human melanoma xenotransplants.
Eberle J; Fecker LF; Hossini AM; Wieder T; Daniel PT; Orfanos CE; Geilen CC
Oncogene; 2003 Dec; 22(57):9131-41. PubMed ID: 14668794
[TBL] [Abstract][Full Text] [Related]
10. Deregulation of the CD95/CD95L system in lymphocytes from patients with primary acute HIV infection.
Cossarizza A; Stent G; Mussini C; Paganelli R; Borghi V; Nuzzo C; Pinti M; Pedrazzi J; Benatti F; Esposito R; Røsok B; Nagata S; Vella S; Franceschi C; De Rienzo B
AIDS; 2000 Mar; 14(4):345-55. PubMed ID: 10770536
[TBL] [Abstract][Full Text] [Related]
11. Neutrophil-dependent tumor rejection and priming of tumoricidal CD8+ T cell response induced by dendritic cells overexpressing CD95L.
Buonocore S; Haddou NO; Moore F; Florquin S; Paulart F; Heirman C; Thielemans K; Goldman M; Flamand V
J Leukoc Biol; 2008 Sep; 84(3):713-20. PubMed ID: 18567840
[TBL] [Abstract][Full Text] [Related]
12. The regulation of CD95 (Fas) ligand expression in primary T cells: induction of promoter activation in CD95LP-Luc transgenic mice.
Norian LA; Latinis KM; Eliason SL; Lyson K; Yang C; Ratliff T; Koretzky GA
J Immunol; 2000 May; 164(9):4471-80. PubMed ID: 10779747
[TBL] [Abstract][Full Text] [Related]
13. CD95 ligand expression as a mechanism of immune escape in breast cancer.
Müschen M; Moers C; Warskulat U; Even J; Niederacher D; Beckmann MW
Immunology; 2000 Jan; 99(1):69-77. PubMed ID: 10651943
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of the alloantibody response by CD95 ligand.
Arai H; Chan SY; Bishop DK; Nabel GJ
Nat Med; 1997 Aug; 3(8):843-8. PubMed ID: 9256273
[TBL] [Abstract][Full Text] [Related]
15. Sunlight-induced basal cell carcinoma tumor cells and ultraviolet-B-irradiated psoriatic plaques express Fas ligand (CD95L).
Gutierrez-Steil C; Wrone-Smith T; Sun X; Krueger JG; Coven T; Nickoloff BJ
J Clin Invest; 1998 Jan; 101(1):33-9. PubMed ID: 9421463
[TBL] [Abstract][Full Text] [Related]
16. The CD95/CD95 ligand system is not the major effector in anticancer drug-mediated apoptosis.
Tolomeo M; Dusonchet L; Meli M; Grimaudo S; D'Alessandro N; Papoff G; Ruberti G; Rausa L
Cell Death Differ; 1998 Sep; 5(9):735-42. PubMed ID: 10200532
[TBL] [Abstract][Full Text] [Related]
17. CD95L/FasL and TRAIL in tumour surveillance and cancer therapy.
Wajant H
Cancer Treat Res; 2006; 130():141-65. PubMed ID: 16610707
[TBL] [Abstract][Full Text] [Related]
18. T cell-mediated, IFN-gamma-facilitated rejection of murine B16 melanomas.
Böhm W; Thoma S; Leithäuser F; Möller P; Schirmbeck R; Reimann J
J Immunol; 1998 Jul; 161(2):897-908. PubMed ID: 9670968
[TBL] [Abstract][Full Text] [Related]
19. [Cytotoxic effect of HepG2 cell expressing CD95L in an autocrine and paracrine way].
Zhu Y; Luo K; Wang J
Zhonghua Gan Zang Bing Za Zhi; 1999 Jun; 7(2):69-71. PubMed ID: 10488409
[TBL] [Abstract][Full Text] [Related]
20. Peripheral T and putative natural killer cell lymphomas commonly coexpress CD95 and CD95 ligand.
Ng CS; Lo ST; Chan JK
Hum Pathol; 1999 Jan; 30(1):48-53. PubMed ID: 9923926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
